Pipeline

Mpox Vaccine (SCV-SMPOX)

Our lead vaccine, targeting mpox disease, is being positioned to address the lack of vaccine supply options currently impacting the response to the African outbreak of Mpox, declared by the World Health Organisation as Public Health Emergency of International Concern.

Sementis’ MPOX vaccine (SCV-SMPOX) has been de-risked and is ready to accelerate into a Clinical Development Program.

SCV-SMPOX is positioned to demonstrate the capacity of the SCV Vaccine Platform for manufacturing at scale. 

Peanut Vaccine (SCV-PHAV)

Peanut allergy is a potentially life-threatening condition where the body’s immune system mistakenly identifies even small amounts of peanut as harmful. The condition usually presents in early years, can be unpredictable in occurrence and presentation, and prevalence continues to rise. Until recently there was no treatment and peanut avoidance the only way to avoid allergic reactions.

Sementis’ SCV-Peanut Hypoallergenic Vaccine (SCV-PHAV) immunotherapy is designed to induce a long-lived immune response to tolerate peanut allergens.  It can potentially address an unmet market for allergy treatment – a short-regimen, durable, and safe option.

SCV-PHAV demonstrates the utility of the SCV Vaccine Platform in immune-modulation applications. 

COVID Vaccine (SCV-SMN)

Current COVID-19 vaccines only target the spike protein of SARS-CoV-2, a part of the virus that mutates frequently. This means these vaccines need regular updates to stay effective against new variants. While the risk of another coronavirus-driven pandemic remains, there’s an urgent need for a vaccine that offers protection against a broader range of coronavirus family members (pan-coronavirus).

Sementis’ SCV-Spike-Membrane-Nucleocapsid vaccine (SCV-SMN) expresses multiple SARS-CoV-2 antigens (spike, membrane, nucleocapsid) in a singular vector. By targeting and including multiple conserved regions of the SARS-CoV2 virus, SCV-SMN could be positioned as a pan-coronavirus vaccine.

SCV-SMN demonstrates the capacity of the SCV Vaccine Platform for accommodating multiple antigens and unstable immunogens. 

Chikungunya/Zika vaccine (SCV1002)

Diseases brought about by chikungunya virus and Zika virus have limited vaccine options. Sementis has developed a combination vaccine that can be used for prophylactic treatments of chikungunya and Zika virus diseases.

This prototype vaccine leverages the unique characteristic of SCV by including two different disease antigens in the same vector.

Single shot efficacy with a strong and sustained immune response has been demonstrated in NHP models.

SCV1002 demonstrates the utility of the SCV Vaccine Platform for combination vaccines against multiple diseases.